Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

References 

1. Giles FJ, Keating A, Goldstone AH, et al. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2002;73–110
2. Giles F, Estey E, O’Brien S . Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095–2104
   • CrossRef
3. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277–4283
   • MEDLINE
   • CrossRef
4. Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165–4172
5. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343–4349
   • MEDLINE
   • CrossRef
6. Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.. Oncology (Huntingt). 2000;14:9–11
7. Yang YC, Yin T. Interleukin-11 and its receptor. Biofactors. 1992;4:15–21
   • MEDLINE
8. Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE. 2003;2003:PE40
   • MEDLINE
9. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575–3583
   • MEDLINE
   • CrossRef
10. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–458
    • MEDLINE
    • CrossRef
11. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;1905–1911
12. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187–220
13. Cox DR, Oakes D. Analysis of Survival Data. New York: Chapman Hall; 1984;
14. Du X, Liu Q, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol. 1997;G545–G552
15. Ellis M, Zwaan F, Hedstrom U, et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:275–280
    • Abstract
    • Full Text
    • Full-Text PDF (103 KB)
    • CrossRef
16. Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;2177–2187
17. Kantarjian HM, Cortes JE, O’Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;97–100
18. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;994–1004
19. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;116–121
20. Ault P, Kantarjian H, Welch MA, et al. Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res. 2004;613–618
21. Du X, Williams DA . Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997;3897–3908
22. Teramura M, Kobayashi S, Yoshinaga K, et al. Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol. 1996;38(Suppl.):S099–S102